Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in relapsed or refractory multiple myeloma
NL-OMON50498Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of daratumumab and hyaluronidase in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Observed pre-dose serum concentration of daratumumab at Cycle 3 Day 1 and Safety and tolerability. Started Feb 2016; status: active, not recruiting.
02
Drugs
daratumumabhyaluronidase
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON50498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50498.